Boehringer Plans Filing For Nerandomilast After Second Phase III Hits

 
• By Jessica Merrill

The PDE4B inhibitor showed improvement in lung function in patients with progressive pulmonary fibrosis in a second positive Phase III trial in pulmonary fibrosis.

(Shutterstock)

More from Respiratory

More from Therapy Areas